Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lorelei Ann Mucci, Sc.D.

Co-Author

This page shows the publications co-authored by Lorelei Mucci and Konrad Stopsack.
Connection Strength

5.258
  1. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020 07 14; 41(7):904-908.
    View in: PubMed
    Score: 0.910
  2. Regular aspirin use and gene expression profiles in prostate cancer patients. Cancer Causes Control. 2018 Aug; 29(8):775-784.
    View in: PubMed
    Score: 0.788
  3. Common medications and prostate cancer mortality: a review. World J Urol. 2017 Jun; 35(6):875-882.
    View in: PubMed
    Score: 0.692
  4. Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors. Clin Cancer Res. 2021 Oct 19.
    View in: PubMed
    Score: 0.248
  5. Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. Clin Cancer Res. 2020 11 15; 26(22):5903-5913.
    View in: PubMed
    Score: 0.230
  6. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020 10; 78(4):637-639.
    View in: PubMed
    Score: 0.227
  7. The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer. 2020 08; 123(4):657-665.
    View in: PubMed
    Score: 0.225
  8. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020 06; 10(6):779-782.
    View in: PubMed
    Score: 0.223
  9. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.217
  10. Aneuploidy drives lethal progression in prostate cancer. Proc Natl Acad Sci U S A. 2019 06 04; 116(23):11390-11395.
    View in: PubMed
    Score: 0.210
  11. Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 04; 28(4):707-714.
    View in: PubMed
    Score: 0.205
  12. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. Eur Urol. 2019 07; 76(1):33-40.
    View in: PubMed
    Score: 0.201
  13. A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev. 2018 10; 27(10):1231-1233.
    View in: PubMed
    Score: 0.199
  14. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017 08 01; 38(8):806-811.
    View in: PubMed
    Score: 0.185
  15. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res. 2016 08 15; 76(16):4785-90.
    View in: PubMed
    Score: 0.172
  16. Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. J Natl Cancer Inst. 2021 Jun 01; 113(6):727-734.
    View in: PubMed
    Score: 0.060
  17. Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors. Clin Cancer Res. 2021 03 15; 27(6):1792-1806.
    View in: PubMed
    Score: 0.059
  18. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clin Cancer Res. 2020 04 15; 26(8):2047-2064.
    View in: PubMed
    Score: 0.054
  19. Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 06; 28(6):1052-1058.
    View in: PubMed
    Score: 0.052
  20. Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res. 2019 02; 17(2):446-456.
    View in: PubMed
    Score: 0.050
  21. Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival. Prostate. 2019 01; 79(1):73-80.
    View in: PubMed
    Score: 0.050
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.